GlobeNewswire RSS FeedContains the last 20 releasesuuid:fecdc4d6-be7c-4bcd-8e4c-4dc2384d0598;id=487872024-03-28T15:05:00Znewsdesk@globenewswire.com (NewsDesk)http://www.globenewswire.com/LegacyRss?Length=4newsdesk@globenewswire.comhttps://www.globenewswire.com/news-release/2024/03/28/2854210/0/en/Autoimmune-Hepatitis-Diagnosis-and-Treatment-Market-Size-to-Reach-USD-19-15-Bn-by-2032.htmlAutoimmune Hepatitis Diagnosis and Treatment Market Size to Reach USD 19.15 Bn by 20322024-03-28T15:05:00Z2024-03-28T15:09:39ZThe global autoimmune hepatitis diagnosis and treatment market size was valued at USD 14.03 billion in 2023 and is expected to reach around USD 19.15 billion by 2032, growing at a CAGR of 3.3% between 2023 and 2032.]]>2854210enGlobeNewswire Inc.Precedence ResearchThu, 28 Mar 2024 15:05 GMTMarket Research ReportsTowards HealthcarePrecedence Researchhttps://www.globenewswire.com/news-release/2024/03/28/2854196/28124/en/Flexible-Electronics-Global-Business-Report-2024-Advances-in-Organic-Electronics-and-Flexible-Sensors-Extend-Application-of-Flexible-Electronics-in-Soft-Robotics.htmlFlexible Electronics Global Business Report 2024 - Advances in Organic Electronics and Flexible Sensors Extend Application of Flexible Electronics in Soft Robotics2024-03-28T14:59:39Z2024-03-28T15:09:39ZDublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Flexible Electronics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.
The global market for Flexible Electronics estimated at US$26.6 Billion in the year 2023, is projected to reach a revised size of US$89.2 Billion by 2030, growing at a CAGR of 16.3% over the analysis period 2023-2030.
Electronic Displays, one of the segments analyzed in the report, is projected to record 15.8% CAGR and reach US$52.9 Billion by the end of the analysis period. Growth in the Flexible Electronic Batteries segment is estimated at 19.6% CAGR for the next 8-year period.
The Flexible Electronics market in the U.S. is estimated at US$4.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$40.5 Billion by the year 2030 trailing a CAGR of 19.4% over the analysis period 2023 to 2030.]]>2854196enGlobeNewswire Inc.Research and MarketsThu, 28 Mar 2024 14:59 GMTResearch Analysis and ReportsElectronic ManufacturingElectronics ManufacturingFlexible ElectronicStretchable ElectronicStretchable Electronicshttps://www.globenewswire.com/news-release/2024/03/28/2854194/28124/en/Global-E-commerce-Packaging-Market-Projected-to-Reach-USD-43-74-Bn-by-2028.htmlGlobal E-commerce Packaging Market Projected to Reach USD 43.74 Bn by 20282024-03-28T14:55:43Z2024-03-28T15:09:39ZDublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Global E-commerce Packaging Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.]]>2854194enGlobeNewswire Inc.Research and MarketsThu, 28 Mar 2024 14:56 GMT ]]>GlobeNewswire Inc.Research Analysis and ReportsBubble WrapE CommerceE Commerce PackagingE-BusinessPackagingSustainable Packaginghttps://www.globenewswire.com/news-release/2024/03/28/2854189/683/en/SHAREHOLDER-ACTION-REMINDER-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-Amplitude.htmlSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amplitude2024-03-28T14:55:00Z2024-03-28T15:09:39ZNEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amplitude, Inc. (“Amplitude” or the “Company”) (NASDAQ: AMPL) and reminds investors of the April 15, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. ]]>2854189enGlobeNewswire Inc.Faruqi & Faruqi LLPThu, 28 Mar 2024 14:55 GMT ]]>GlobeNewswire Inc.Class ActionLaw & Legal IssuesFaruqi & FaruqiFaruqi LawClass ActionClass Action LawsuitNASDAQAMPLAmplitude IncAmplitudehttps://www.globenewswire.com/news-release/2024/03/28/2854187/28124/en/Global-Real-World-Evidence-Solutions-Market-Predicted-to-Reach-4-6-Billion-by-2030-with-Rapid-Growth-Through-Digital-Transformation-in-Healthcare.htmlGlobal Real World Evidence Solutions Market Predicted to Reach $4.6 Billion by 2030 with Rapid Growth Through Digital Transformation in Healthcare2024-03-28T14:48:41Z2024-03-28T15:09:39ZDublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Global Real World Evidence Solutions Market Size, Share & Trends Analysis Report by Component (Services, Data Sets), Application, End-use, Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.]]>2854187enGlobeNewswire Inc.Research and MarketsThu, 28 Mar 2024 14:49 GMTResearch Analysis and ReportsContract Research OrganizationReal World EvidenceReal World Evidence SolutionReal World Evidence Solutionshttps://www.globenewswire.com/news-release/2024/03/28/2854182/28124/en/Global-eClinical-Solutions-Market-Expected-to-Reach-USD-22-7-Billion-by-2030-Driven-by-Technological-Advancements.htmlGlobal eClinical Solutions Market Expected to Reach USD 22.7 Billion by 2030 Driven by Technological Advancements 2024-03-28T14:43:38Z2024-03-28T15:09:39ZDublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Global eClinical Solutions Market Size, Share & Trends Analysis Report by Product (Clinical Trial Management, Clinical Analytics Platforms), Delivery Mode (Web & Cloud Based, On-premise), Development Phase, End-use, Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.]]>2854182enGlobeNewswire Inc.Research and MarketsThu, 28 Mar 2024 14:43 GMTResearch Analysis and ReportsClinical AnalyticsClinical Trial ManagementE ClinicalE Clinical SolutionsEClinicaleClinical Solutionshttps://www.globenewswire.com/news-release/2024/03/28/2854181/28124/en/North-America-Sharps-Containers-Market-Projected-to-Reach-US-247-28-Million-by-2030-Amid-Rising-Medical-Waste.htmlNorth America Sharps Containers Market Projected to Reach US$ 247.28 Million by 2030 Amid Rising Medical Waste.2024-03-28T14:40:46Z2024-03-28T15:09:39ZDublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "North America Sharps Containers Market Forecast to 2030 - Regional Analysis - by Product, Usage, Waste Type, Waste Generators, Container Size, and Distribution Channel" report has been added to ResearchAndMarkets.com's offering.]]>2854181enGlobeNewswire Inc.Research and MarketsThu, 28 Mar 2024 14:41 GMT ]]>GlobeNewswire Inc.Research Analysis and ReportsGenerators Medical DevicesMedical SuppliesSharp ContainerSharps ContainerSharps Disposalhttps://www.globenewswire.com/news-release/2024/03/28/2854178/28124/en/Global-Complementary-And-Alternative-Medicine-Market-Projected-to-Reach-USD-192-41-Billion-by-2028-Growing-at-a-CAGR-of-12-1.htmlGlobal Complementary And Alternative Medicine Market Projected to Reach USD 192.41 Billion by 2028, Growing at a CAGR of 12.1%2024-03-28T14:36:41Z2024-03-28T15:09:39ZDublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Global Complementary And Alternative Medicine Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.]]>2854178enGlobeNewswire Inc.Research and MarketsThu, 28 Mar 2024 14:37 GMT ]]>GlobeNewswire Inc.Research Analysis and ReportsAlternative Health TherapiesAlternative MedicineAlternative TreatmentAyurvedaAyurvedicAYUSHYogahttps://www.globenewswire.com/news-release/2024/03/28/2854157/0/en/Mayfair-Gold-Receives-Shareholder-Meeting-Requisition.htmlMayfair Gold Receives Shareholder Meeting Requisition2024-03-28T14:01:35Z2024-03-28T15:09:39ZReiterates Commitment to Constructive Dialogue and Engagement with all Shareholders]]>2854157enGlobeNewswire Inc.Mayfair Gold Corp.Thu, 28 Mar 2024 14:01 GMTMajor shareholder announcementsMayfair GoldCanadametalsmininggoldshareholder meetinghttps://www.globenewswire.com/news-release/2024/03/28/2854092/0/en/Vaxxinity-to-Present-Clinical-Data-at-the-Annual-Academy-of-Neurology-2024-Annual-Meeting.htmlVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting2024-03-28T13:23:21Z2024-03-28T15:09:39ZPresentation will address the Company’s clinical data in Parkinson’s disease]]>2854092enGlobeNewswire Inc.Vaxxinity, Inc.Thu, 28 Mar 2024 13:23 GMTCalendar of Eventshttps://www.globenewswire.com/news-release/2024/03/28/2854087/0/en/Omega-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Strategic-Update.htmlOmega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update2024-03-28T13:15:05Z2024-03-28T15:09:39ZCAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the fourth quarter and full year ended December 31, 2023, and a strategic prioritization initiative to focus resources on near-term milestones to support long-term shareholder value.]]>2854087enGlobeNewswire Inc.Omega TherapeuticsThu, 28 Mar 2024 13:15 GMTEarnings Releases and Operating Resultshttps://www.globenewswire.com/news-release/2024/03/28/2854078/0/en/UCLOUDLINK-GROUP-INC-Files-2023-Annual-Report-on-Form-20-F.htmlUCLOUDLINK GROUP INC. Files 2023 Annual Report on Form 20-F2024-03-28T13:05:00Z2024-03-28T15:09:39ZHONG KONG, March 28, 2024 (GLOBE NEWSWIRE) -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (the “SEC”) on March 28, 2024. ]]>2854078enGlobeNewswire Inc.uCloudlink Group Inc.Thu, 28 Mar 2024 13:05 GMTAnnual reporthttps://www.globenewswire.com/news-release/2024/03/28/2854035/0/en/Coveo-Introduces-Two-New-Groundbreaking-GenAI-Business-Applications-and-15-AI-Innovations-in-the-New-Coveo-Spring-Release.htmlCoveo Introduces Two New Groundbreaking GenAI Business Applications and 15+ AI Innovations in the New Coveo Spring Release2024-03-28T13:00:00Z2024-03-28T15:09:39Z2854035enGlobeNewswire Inc.Coveo Solutions Inc.Thu, 28 Mar 2024 13:00 GMT ]]>GlobeNewswire Inc.Product / Services AnnouncementAICanada TechnologyGenerative AIContact CenterCustomer Servicecustomer experienceGenAIenterprise searchhttps://www.globenewswire.com/news-release/2024/03/28/2854050/0/en/GeoVax-to-Present-Data-on-GEO-CM04S1-a-Next-Generation-Covid-19-Vaccine-at-the-World-Vaccine-Congress.htmlGeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress2024-03-28T13:00:00Z2024-03-28T15:09:39ZATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation Covid-19 vaccine candidate, during the upcoming 24th Annual World Vaccine Congress taking place in Washington, DC on April 1-4, 2024. ]]>2854050enGlobeNewswire Inc.GeoVax, Inc.Thu, 28 Mar 2024 13:00 GMTCompany AnnouncementGeoVaxGEO-CM04S1HealthcareCOVID-19https://www.globenewswire.com/news-release/2024/03/28/2854028/28124/en/Molecular-Point-of-Care-mPOC-Global-Market-Analysis-and-Future-Potential-Market-Sizing-Forecasting-Trend-Mapping-and-Competitive-Analysis.htmlMolecular Point-of-Care (mPOC) Global Market Analysis and Future Potential: Market Sizing, Forecasting, Trend Mapping and Competitive Analysis 2024-03-28T12:51:39Z2024-03-28T15:09:39ZDublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition" report has been added to ResearchAndMarkets.com's offering.]]>2854028enGlobeNewswire Inc.Research and MarketsThu, 28 Mar 2024 12:51 GMTResearch Analysis and ReportsMolecular Point of CaremPOCPOC Molecular DiagnosticsPoint of Care TestingPoint-of-Care DiagnosticsRapid TestSARS CoV 2https://www.globenewswire.com/news-release/2024/03/28/2854016/0/en/Reborn-Coffee-Reports-Fiscal-Year-2023-Financial-Results.htmlReborn Coffee Reports Fiscal Year 2023 Financial Results2024-03-28T12:31:00Z2024-03-28T15:09:39Z2854016enGlobeNewswire Inc.REBORN COFFEE, INC.Thu, 28 Mar 2024 12:31 GMTEarnings Releases and Operating Resultshttps://www.globenewswire.com/news-release/2024/03/28/2853993/0/en/TransCode-Therapeutics-Announces-Appointment-of-Daniel-Vlock-M-D-as-Chief-Medical-Officer.htmlTransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer2024-03-28T12:30:00Z2024-03-28T15:09:39Z2853993enGlobeNewswire Inc.TransCode Therapeutics, Inc.Thu, 28 Mar 2024 12:30 GMTDirectors and OfficersbiotechnologyCMOoncologyclinical trialRNAdeliverymetastasisoligonucleotidecancernanoparticlebreast cancerhttps://www.globenewswire.com/news-release/2024/03/28/2853986/28124/en/Global-Legal-Practice-Management-Software-Market-Projected-to-Reach-4-74-Billion-by-2028.htmlGlobal Legal Practice Management Software Market Projected to Reach $4.74 Billion by 20282024-03-28T12:26:46Z2024-03-28T15:09:39ZDublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Global Legal Practice Management Software Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.]]>2853986enGlobeNewswire Inc.Research and MarketsThu, 28 Mar 2024 12:27 GMT ]]>GlobeNewswire Inc.Research Analysis and ReportsCase Management SoftwareeDiscovery SoftwareLegal SystemPractice Management SoftwareSoftwarehttps://www.globenewswire.com/news-release/2024/03/28/2853964/29489/en/AIM-ImmunoTech-to-Present-at-the-MedInvest-Biotech-Pharma-Investor-Conference.htmlAIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference2024-03-28T12:05:00Z2024-03-28T15:09:39ZLive webcast presentation on Wednesday, April 3rd at 1:35 PM ET]]>2853964enGlobeNewswire Inc.AIM ImmunoTech Inc.Thu, 28 Mar 2024 12:05 GMTCalendar of EventsampligenrintatolimodoncologyImmuno-Oncologycancerbreast cancerpancreatic cancerovarian cancercovid-19long covidhttps://www.globenewswire.com/news-release/2024/03/28/2853967/0/en/Tevogen-Bio-Reports-Series-A-1-Preferred-Stock-Investment-at-10-Conversion-Price.htmlTevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price2024-03-28T12:05:00Z2024-03-28T15:09:39Z2853967enGlobeNewswire Inc.Tevogen Bio IncThu, 28 Mar 2024 12:05 GMTChanges in company's own sharesbiotechTcellOncologyLongCOVIDMultiple sclerosisbiotech AICOVID B cell malignancyCOVID immune compromisedTVGNaffordable